Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)

Key facts

Sponsor

Gachon University Gil Medical Center

Intervention

Combination therapy(drug)

Enrollment

64 enrolled

Eligibility

19 years · All sexes

Timeline

2025 – 2027

Study locations (15)

• Pusan National University Hospital, Busan, South Korea
• Chungbuk National University Hospital, Chungju, South Korea
• Keimyung University Dongsan Hospital, Daegu, South Korea
• Chungnam National University Hospital, Daejeon, South Korea
• Chonnam National University Hospital, Gwangju, South Korea
• Incheon Sejong Hospital, Incheon, South Korea
• Gachon University Gil Hospital, Incheon, South Korea
• Seoul National University Hospital, Seoul, South Korea
• Yonsei University Health System, Severance Hospital, Seoul, South Korea
• Asan Medical Center, Seoul, South Korea
• Samsung Medical Center, Seoul, South Korea
• The Catholic University of Korea, Seoul St.Mary, Seoul, South Korea
• Koera University Guro Hospital, Seoul, South Korea
• Yonsei University, Wonju Severance Christian Hospital, Wŏnju, South Korea
• Pusan National University Yangsan Hospital, Yangsan, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Heritable pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07498244
  Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients
  Medical University of Graz
• RECRUITINGNANCT07079592
  A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension
  National Defense Medical Center, Taiwan
• RECRUITINGPHASE2NCT07073820
  A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
  Pfizer
• RECRUITINGNCT07537517
  Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.
  Hospital General Universitario Gregorio Marañon
• RECRUITINGNANCT07120789
  Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension
  University of Sao Paulo General Hospital
• RECRUITINGNANCT07576894
  Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease
  University of Colorado, Denver
• RECRUITINGNCT07087613
  Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
  Eko Devices, Inc.
• RECRUITINGNANCT06850792
  imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
  University of Sao Paulo General Hospital

See all trials for Heritable pulmonary arterial hypertension →